Back
Science

Discontinuing LAMA or ICS in COPD Linked to Increased Exacerbation Risk for Three Months

Generated on: Last updated: 1 sources
View source

FLAME Trial Post Hoc Analysis: Short-Term Consequences of LAMA or ICS Discontinuation in COPD

A post hoc analysis of the FLAME trial investigated the short-term consequences of discontinuing long-acting muscarinic antagonists (LAMA) or inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). The study aimed to determine if early shifts in exacerbation patterns indicated withdrawal effects after stopping these inhaled therapies.

Original FLAME Trial Background

The original FLAME trial was a 52-week, double-blind study that compared a long-acting beta-2 agonist (LABA) plus LAMA regimen with a LABA plus ICS regimen. It involved 3,362 patients with moderate-to-severe COPD and a history of exacerbations.

Methodology of the Post Hoc Analysis

Participants were categorized based on their baseline use of LAMA or ICS. Exacerbation outcomes in the first three months were compared with those in later periods for individuals who either continued or discontinued their treatment. Multivariable mixed-effects models were employed to assess differences in exacerbation rates.

Key Findings

  • LAMA Discontinuation: Stopping LAMA was associated with a notable, temporary increase in moderate-to-severe exacerbations during the first three months compared to later periods (p=0.001). In a subgroup less influenced by concomitant ICS use, the rate ratio increased up to 2.2 (95% CI 1.2–4.1) during this early phase. A similar signal was not confirmed for severe exacerbations, which the authors attributed to low event counts.

  • ICS Discontinuation: Discontinuing ICS was linked to a significant early increase in severe exacerbations (p=0.023). However, the difference for moderate-to-severe events did not achieve statistical significance. The observed ICS withdrawal effects appeared consistent regardless of the patient's baseline blood eosinophil count.

Clinical Implications

The findings suggest that discontinuing either LAMA or ICS may result in meaningful, time-limited increases in COPD exacerbations. This reinforces the importance for clinicians to support patient adherence to treatment and to plan therapy changes with an awareness that the initial three months following discontinuation may represent a period of higher risk.